{
    "id": "correct_subsidiary_00047_0",
    "rank": 69,
    "data": {
        "url": "https://www.ajpharm.com/our-board/",
        "read_more_link": "",
        "language": "en",
        "title": "Our Board – AnnJi Pharmaceutical Co. Ltd",
        "top_image": "https://www.ajpharm.com/wp-content/uploads/2021/02/butterfly-150x150.png",
        "meta_img": "https://www.ajpharm.com/wp-content/uploads/2021/02/butterfly-150x150.png",
        "images": [
            "https://www.ajpharm.com/wp-content/uploads/2021/02/cropped-logo-152x53.png",
            "https://www.ajpharm.com/wp-content/uploads/2021/02/wlogo-768x131.png",
            "https://www.ajpharm.com/wp-content/uploads/2021/02/Logo-01-White.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://www.ajpharm.com/wp-content/uploads/2021/02/butterfly-150x150.png",
        "meta_site_name": "",
        "canonical_link": "https://www.ajpharm.com/our-board/",
        "text": "About AnnJi Pharmaceutical Co. Ltd\n\nDedicated to New Drug Development in Dermatology & Neurology\n\nMeet Our Board Members\n\nWendy Huang, Ph.D.\n\nChair & CEO\n\nAnnJi Pharmaceutical\n\nPh.D. in Toxicology, North Carolina State University\n\nForty years pharmaceutical career across multiple therapeutic areas, medical devices and cosmetic products.\n\nHeld R&D Leadership and executive positions in multinational companies, including GSK, Stiefel Labs, Connetics Corp., Dermik Laboratories, and Sanofi-Aventis.\n\nA strong track record in global product development and organizational development.\n\nLead and contributed to more than 10 market authorizations of new drug products and medical devices.\n\nJerome Shen, Ph.D.\n\nGeneral Partner/Head of Life Science Investments\n\nTaiwania Capital\n\nPh.D. in Chemical Engineering at the University of Wisconsin, Madison\n\nThe President and co-founder of Allgenesis Biotherapeutics Inc., a new drug development company addressing the unmet medical needs in the ophthalmology areas since 2014.\n\nBefore Allgenesis, he was an executive with venture capital firms for 20 years; focusing on investment in the life science and biotech/pharmaceutical industry.\n\nHe also took the leading roles in several biotech start-ups, responsible for corporate development and strategic initiatives and planning.\n\nThe Secretary-General of Taiwan Biotech Association, a non-profit organization, from 2005 to 2008.\n\nCalvin Tsai\n\nDirector of the Board / CEO of Orient EuroPharma CO., Ltd.\n\nBusiness Administration, University of California, Riverside\n\nDirector of the Board / CEO of Orient Pharma CO., Ltd.\n\nChairman of OP NanoPharma Co., Ltd.\n\nLegal representative person of Babecare Co., Ltd.\n\nDirector of the Board of Hung Lu Foundation\n\nIndependent director of Simple Mart Retail Co., Ltd.\n\nPierre Fabre Medicament, UK – Assistant Product Manager\n\nDeloitte & Touché – Auditor II\n\nElan Pharmaceutical Co., San Diego – Financial Analyst / Financial Liaison of Sales and Marketing Division\n\nWilly Huang\n\nProject Vice General Manager\n\nFubon Financial Holding Venture Capital\n\nMaster Degree in Institute of Microbiology & Immunology, National Yang Ming Chiao Tung University, Taiwan​\n\nProject Vice General Manager, Fubon Financial Holding Venture Capital​\n\nSales Representative, Novartis Taiwan Co Ltd.​\n\nManager, China Chemical & Pharmaceutical Co., Ltd.​\n\nInvestment Manager, CDIB BIOSCIENCE VENTURE MANAGEMENT (BVI), INC.​\n\nDean Chuang\n\nDirector of President International Development Corp.\n\nM.S. in Genetics, National Yang-Ming University\n\nOver ten years of experience in the biotech/healthcare investments in Taiwan, US, and China. Deeply involved in several licensing deals and M&A transactions.\n\nMichael Huang\n\nManaging Partner\n\nTaiwania Capital\n\nMBA, Rice University\n\nM.A. in Chemistry, University of Texas, Arlington\n\nPrior to joining Taiwania as a Managing Partner, Michael was the co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the development of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed out-licensing deals with Sihuan Pharmaceutical and Sanofi Korea.\n\nOver 18 years of experience as a venture capitalist, focusing on investments in life science startups in the US, Taiwan, and Japan.\n\nExpertized in investing and managing early to late-stage biotech and medical device companies in Greater China, Japan, European and North America regions.\n\nTaiwan’s leading new drug developer in dermatology & neurology\n\nTranslation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept"
    }
}